The Rome V international diagnostic criteria for all disorders of gut-brain interaction, of which IBS is the most common, has been published in the May 2026 issue of the medical journal Gastroenterology, and presented publicly earlier this month to the gastroenterology professional community at Digestive Disease Week, a major annual professional conference in the field. Rome V involved 7 years of development and over 140 expert researchers in the DGBI field from 27 countries. There are some revisions specific to IBS detailed in the article below.

https://www.gastrojournal.org/issue/S0016-5085(25)X0007-X

Rome I was established in 1990, Rome II in 1999, Rome III in 2006, Rome IV in 2016, and now Rome V in 2026. Over the years, experts have considered a Rome criteria diagnosis of IBS 98% accurate with few or no tests for most people. Each version of the criteria has built on the foundations of the preceding decades, while incorporating the new research insights and treatment interventions since the previous version. In Rome V, the research community clearly establishes “disorders of gut-brain interaction” as the current preferred term, continues its efforts to make the criteria useful internationally in many languages and cultural contexts,  to guide health care professional colleagues, not only in gastroenterology, but also primary care and unrelated specialties, to understand and use the criteria and accompanying treatment algorithms appropriately, and to advocate that DBGI-affected people have access to the full range of evidence-based medical, psychological, and dietary interventions that their particular situations require.

IBS Impact will add more information to this website, the blog and social media on Rome V as more details become available. Thank you to all DGBI professionals worldwide, especially those who worked long and hard on Rome V, for your continued dedication every day to the field and to individuals with DGBI, including IBS.

Posted May 2026